<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonislet cell tumor hypoglycemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonislet cell tumor hypoglycemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nonislet cell tumor hypoglycemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian Vella, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irl B Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypoglycemia can be caused by several tumors, including islet and nonislet tumors. Nonislet cell tumor hypoglycemia (NICTH) is a rare but serious complication of malignancy [<a href="#rid1">1,2</a>]. The most common cause of this type of hypoglycemia is tumoral overproduction of incompletely processed insulin-like growth factor 2 (IGF-2), which results in stimulation of the insulin receptors and increased glucose utilization. Other potential but less common causes include the production of autoantibodies against insulin or the insulin receptor and extensive tumor burden resulting in destruction of the liver or adrenal glands. NICTH occurs more commonly in patients with mesenchymal tumors, fibromas, carcinoid, myelomas, lymphomas, hepatocellular, and colorectal carcinomas  (<a class="graphic graphic_table graphicRef69283" href="/z/d/graphic/69283.html" rel="external">table 1</a>) [<a href="#rid2">2-5</a>].</p><p>The pathophysiology, clinical manifestations, and diagnostic evaluation of NICTH will be reviewed here. Islet cell tumors (insulinomas), other causes of hypoglycemia, and the diagnostic approach to hypoglycemic disorders in general are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma"</a> and  <a class="medical medical_review" href="/z/d/html/1763.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, causes, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Severe hypoglycemia has been observed in a small percentage of patients with nonislet cell tumors, usually of mesenchymal (eg, fibrosarcoma), vascular (eg, hemangiopericytoma), or epithelial cell types  (<a class="graphic graphic_table graphicRef69283" href="/z/d/graphic/69283.html" rel="external">table 1</a>) [<a href="#rid1">1-5</a>]. Among tumors of epithelial cell origin, hepatocellular carcinomas are most common [<a href="#rid2">2,6</a>]. The tumors are usually large in size, weighing on average 2 to 4 kilograms; they are located in the chest in approximately one-third and in the retroperitoneal region in two-thirds of cases.</p><p>No single pathogenetic mechanism explains all cases of nonislet cell tumor hypoglycemia (NICTH). However, the major cause of NICTH appears to be increased glucose utilization (particularly in skeletal muscle) and inhibition of glucose release from the liver due to tumoral secretion of incompletely processed insulin-like growth factor 2 (IGF-2), termed pro-IGF-2 [<a href="#rid6">6-11</a>], or rarely, IGF-1 [<a href="#rid12">12</a>]. In one series of 28 patients with NICTH, for example, 25 had elevated serum pro-IGF-2 concentrations; the concentration of normal IGF-2 was reduced [<a href="#rid10">10</a>]. Pro-IGF-2 also suppresses <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a> and growth hormone release [<a href="#rid6">6</a>]. The net result is continued glucose utilization by skeletal muscle and inhibition of glucose release, glycogenolysis, and gluconeogenesis in the liver [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3801.html" rel="external">"Physiology of insulin-like growth factor 1"</a>.)</p><p>Nonislet tumors can secrete insulin, although it is uncommon [<a href="#rid13">13-15</a>]. In one report of NICTH associated with a cervical cancer, in situ hybridization confirmed the presence of proinsulin mRNA in the tumor, providing evidence for tumoral insulin production [<a href="#rid16">16</a>].</p><p>Another potential mechanism includes extensive replacement of hepatic tissue by tumor with or without glucocorticoid deficiency due to extensive replacement of the adrenal glands by tumor or hemorrhage [<a href="#rid17">17</a>].</p><p>In the first case report of a patient with metastatic hepatocellular carcinoma and severe hypoglycemia, extensive postmortem examination found no abnormality in the pancreas, extracts from the liver tumor contained no insulin, and the glycogen content was low in the liver (in contrast to the abundant hepatic glycogen in patients with hyperinsulinism) and absent in the tumor [<a href="#rid18">18</a>]. Thus, severe hypoglycemia was mediated by mechanisms other than excess insulin and likely due to extensive tumor burden in the liver.</p><p class="headingAnchor" id="H11465817"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with nonislet cell tumor hypoglycemia (NICTH) may appear ill due to the underlying tumor, particularly when the mechanism of hypoglycemia is extensive tumor burden in the liver. In such patients, common symptoms are weight loss and abdominal pain [<a href="#rid6">6</a>].</p><p>In one series of patients with insulin-like growth factor 2 (IGF-2)-producing tumors, however, hypoglycemia was the initial presentation of the tumor in 48 percent (31 of 65 cases), whereas the tumor was present before the onset of hypoglycemia in 52 percent (34 cases) [<a href="#rid19">19</a>]. Symptoms of hypoglycemia more often occur in the fasting state and may include confusion, lethargy, diaphoresis, or progressive somnolence, with some patients presenting with coma as the initial manifestation of hypoglycemia [<a href="#rid2">2</a>]. Hypokalemia may be present in patients with IGF-2 secreting tumors, likely secondary to the insulin–like activity of pro-IGF-2 [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>The diagnosis of nonislet cell tumor hypoglycemia (NICTH) is based upon clinical and biochemical findings  (<a class="graphic graphic_table graphicRef56314" href="/z/d/graphic/56314.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1363559563"><span class="h2">Clinical findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient with known tumor burden</strong> – Regardless of the mechanism of NICTH, the identification of this disorder is not usually difficult. When a patient with known tumor burden is found to be hypoglycemic, the cause is typically apparent from the history and physical examination. In these cases, a search for other causes of hypoglycemia is generally unwarranted, especially if the tumor type is known to be associated with hypoglycemia  (<a class="graphic graphic_table graphicRef69283" href="/z/d/graphic/69283.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">The causes of hypoglycemia in patients with known tumors include extensive tumor infiltration, resulting in destruction of the liver or adrenal glands; tumoral production of incompletely processed insulin-like growth factor 2 (pro-IGF-2); or rarely, production of insulin. Dynamic testing can be performed to establish the diagnosis of adrenal insufficiency in patients in whom hypoadrenalism is suspected due to adrenal gland destruction. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'ACTH stimulation tests'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Well-appearing patient</strong> – A healthy-appearing person with episodes of hypoglycemia is less likely to have NICTH, although in some cases, hypoglycemia was the initial event that led to the diagnosis of a tumor [<a href="#rid19">19,20</a>]. In such cases, a detailed evaluation to determine the cause of hypoglycemia is necessary. The diagnostic approach to hypoglycemia is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Initial assessment to determine the etiology'</a>.)</p><p></p><p class="bulletIndent1">The first step is to review the patient's history in detail, including the nature and timing of symptoms (particularly in relationship to meals), existence of underlying illnesses or conditions, medications taken by the individual and by family members, and social history. Clinical evidence for adrenal insufficiency or nonislet cell tumor should be considered. In a patient with documented hypoglycemia, the cause may be apparent from the history and physical examination  (<a class="graphic graphic_table graphicRef78919" href="/z/d/graphic/78919.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef141452" href="/z/d/graphic/141452.html" rel="external">algorithm 1</a>).</p><p></p><p class="headingAnchor" id="H1258400961"><span class="h2">Biochemical findings</span><span class="headingEndMark"> — </span>The initial laboratory evaluation includes measurement of glucose, insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea/meglitinide screening during an episode of hypoglycemia. In contrast to the biochemical findings in individuals with hyperinsulinemic hypoglycemia, patients with NICTH have low serum insulin and C-peptide concentrations during hypoglycemia  (<a class="graphic graphic_table graphicRef56314" href="/z/d/graphic/56314.html" rel="external">table 2</a>) [<a href="#rid21">21,22</a>]. However, the beta-hydroxybutyrate concentration is also low, consistent with insulin-like activity  (<a class="graphic graphic_algorithm graphicRef141454" href="/z/d/graphic/141454.html" rel="external">algorithm 2</a>).</p><p>In patients with low serum insulin, C-peptide, and beta-hydroxybutyrate, the plasma glucose response to <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a> administration can be used to confirm the action of an insulin-like factor. The plasma glucose response to glucagon administration is &gt;25 mg/dL unless there has been extensive tumoral replacement of hepatic tissue, resulting in low hepatic glycogen stores [<a href="#rid22">22,23</a>]. The tumor burden should be apparent on dedicated imaging studies.</p><p class="headingAnchor" id="H902717367"><span class="h2">Additional testing to confirm the diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with known malignancy</strong> – If clinical and biochemical findings are compelling for NICTH, additional assessment is usually not necessary. If the diagnosis remains in question, measurement of serum IGF-1, IGF-2, and pro-IGF-2 (if available) may be helpful. In patients with NICTH mediated by pro-IGF-2, serum pro-IGF-2 and the IGF-2/IGF-1 ratio may be elevated. Nonetheless, hypoglycemia may be due to non-IGF-mediated mechanisms, and, therefore, normal IGF concentrations do not exclude the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Interpretation of supervised fast results'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without known malignancy</strong> – The finding of hypoglycemia with low levels of serum insulin, C-peptide, and beta-hydroxybutyrate (confirmed by repeat testing) in a healthy-appearing person should prompt evaluation for a tumor with cross-sectional imaging of the chest, abdomen, and pelvis [<a href="#rid2">2</a>]. If a tumor is found, evaluation should proceed as with any newly localized tumor. If the diagnosis of NICTH remains in question, serum IGF-1, IGF-2, and pro-IGF-2 (if available) levels should be measured.</p><p></p><p class="headingAnchor" id="H1897083342"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>There are few other disorders that cause hypoglycemia with low levels of serum insulin, C-peptide, and beta-hydroxybutyrate. In patients with nonislet cell tumor hypoglycemia (NICTH), the plasma glucose response to <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a> administration is typically &gt;25 mg/dL. If the glucose response to glucagon is &lt;25 mg/dL, possibilities include extensive tumoral replacement of hepatic tissue, resulting in low hepatic glycogen stores, or an alternative mechanism. Hypoglycemia associated with some medications, such as opiates or alcohol, can produce similar biochemical findings. Although rare in adults, hypoglycemia arising during primary and secondary adrenal insufficiency also can present with similar biochemical findings.</p><p>Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to endogenous insulin. It has been described in patients with multiple myeloma and Hodgkin lymphoma [<a href="#rid24">24,25</a>]. Symptoms can occur postprandially, fasting, or in both states. Serum insulin and C-peptide levels are usually elevated, however, not low. Insulin antibodies (and their affinity for insulin) can be measured to distinguish insulin autoimmune hypoglycemia from other causes of hypoglycemia. Insulin antibodies do not need to be drawn during hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'C-peptide level ≥0.2 mmol/L'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are three components to therapy in patients with nonislet cell tumor hypoglycemia (NICTH):</p><p class="bulletIndent1"><span class="glyph">●</span>Immediate correction of hypoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment directed at the underlying malignancy</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of recurrent hypoglycemia if the tumor cannot be controlled</p><p></p><p class="headingAnchor" id="H1613270"><span class="h2">Acute management</span><span class="headingEndMark"> — </span>The acute management of hypoglycemia is similar to the management of hypoglycemia during the treatment of diabetes. In brief, treatment of severe hypoglycemia, when the patient is unconscious or unable to ingest carbohydrate, requires a subcutaneous or intramuscular injection of <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a> (0.5 to 1.0 mg). Patients brought to the hospital can be treated more quickly by giving 25 g of 50 percent glucose (dextrose) intravenously. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus", section on 'Reversing hypoglycemia'</a>.)</p><p class="headingAnchor" id="H1613276"><span class="h2">Treatment of the tumor</span><span class="headingEndMark"> — </span>The mainstay of therapy for NICTH is treatment of the underlying malignancy. When a tumor is producing insulin-like growth factors (IGFs) or insulin, complete removal of the tumor results in cure of hypoglycemia [<a href="#rid2">2,6</a>]. If surgery is delayed, ongoing management of hypoglycemia includes increasing caloric intake (sometimes via enteral or parenteral feedings) and intravenous glucose or dextrose, if needed.</p><p>If the tumor is not resectable, palliative tumor debulking is usually performed. Depending upon the tumor type, chemotherapy, radiation, cryoablation, radiofrequency ablation, or selective embolization of tumor feeding blood vessels may be used to control the tumor and improve hypoglycemia [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1613282"><span class="h2">Medical therapy</span><span class="headingEndMark"> — </span>In situations where the underlying malignancy cannot be treated, medical therapy is required to prevent recurrent hypoglycemia. Selection of glucose-raising drugs must be done in concert with knowledge of the potential interaction with chemotherapy. Thus, NICTH is often a disorder treated by the oncologist. The presence of hypoglycemia in such patients is generally associated with a poor prognosis. In case series and reports, hypoglycemia was controlled with glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily), <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a>, or <a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">recombinant human growth hormone</a> (rhGH) [<a href="#rid2">2,3,23,27</a>]. Somatostatin analogues and <a class="drug drug_general" data-topicid="9346" href="/z/d/drug information/9346.html" rel="external">diazoxide</a> have not been effective [<a href="#rid2">2,28,29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial medical therapy</strong> – Glucocorticoids (eg, 30 to 60 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent daily) are a reasonable initial therapy. Glucocorticoids decrease the amount of pro-IGF-2 by increasing its clearance [<a href="#rid2">2</a>]. They also impair insulin action. In one review, glucocorticoids were used in 25 percent of the individual cases reviewed [<a href="#rid2">2</a>]. In some cases, hypoglycemia was refractory to high-dose glucocorticoids, particularly in patients with widespread disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory hypoglycemia</strong> – If hypoglycemia persists, patients with IGF-mediated hypoglycemia (and, therefore, a preserved glycemic response to <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a>) may respond to intravenous glucagon infusion (0.06 to 0.30 mg/hour). (See <a class="local">'Biochemical findings'</a> above.)</p><p></p><p class="bulletIndent1">We prefer not to use growth hormone therapy, unless for palliation in end-stage cancer patients with NICTH. Although rhGH hormone at supraphysiologic doses of 3 to 12 mg daily has been successful in many cases [<a href="#rid28">28,30-35</a>], including one pediatric case [<a href="#rid36">36</a>], it also increases IGF-1 and has the potential to increase tumor growth.</p><p></p><p class="bulletIndent1">Growth hormone has been shown to increase IGF-binding protein and acid labile subunit, which bind IGF-2 and prevent interaction with the insulin receptor, thereby reducing hypoglycemia [<a href="#rid2">2,27,30</a>]. In one case report, the addition of growth hormone allowed a reduced dose of glucocorticoids, limiting long-term side effects [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H2360767053"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112842.html" rel="external">"Society guideline links: Hypoglycemia in adults"</a>.)</p><p class="headingAnchor" id="H8741282"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15596.html" rel="external">"Patient education: Low blood sugar in people with diabetes (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> –<strong> </strong>Severe hypoglycemia has been observed in a small percentage of patients with nonislet cell tumors, usually of mesenchymal or epithelial cell types  (<a class="graphic graphic_table graphicRef69283" href="/z/d/graphic/69283.html" rel="external">table 1</a>). (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1">The most common cause of this type of hypoglycemia is tumoral overproduction of an insulin-like factor such as incompletely processed insulin-like growth factor 2 (pro-IGF-2). Other potential mechanisms include extensive replacement of hepatic tissue by tumor; extensive replacement of the adrenal glands by tumor or hemorrhage (with glucocorticoid deficiency); or rarely, tumoral production of insulin. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> –<strong> </strong>Patients with nonislet cell tumors typically appear ill due to the underlying tumor, particularly when the mechanism of hypoglycemia is extensive tumor burden in the liver. However, hypoglycemia may be the initial presentation in patients with IGF-2-producing tumors. Symptoms of hypoglycemia more often occur in the fasting state and may include confusion, lethargy, diaphoresis, or progressive somnolence. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of nonislet cell tumor hypoglycemia (NICTH) is based on clinical and biochemical findings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical findings</strong> –<strong> </strong>When a patient with known tumor burden is found to be hypoglycemic, the cause is typically apparent from the history and physical examination. In these cases, a search for other causes of hypoglycemia is generally unwarranted, especially if the tumor type is known to be associated with hypoglycemia  (<a class="graphic graphic_table graphicRef69283" href="/z/d/graphic/69283.html" rel="external">table 1</a>). (See <a class="local">'Clinical findings'</a> above.)</p><p></p><p class="bulletIndent2">Although a healthy-appearing person with episodes of hypoglycemia is less likely to have NICTH, a detailed evaluation to determine the cause of hypoglycemia is necessary  (<a class="graphic graphic_algorithm graphicRef141452" href="/z/d/graphic/141452.html" rel="external">algorithm 1</a>). In a patient with documented hypoglycemia, the cause may be apparent from the history and physical examination  (<a class="graphic graphic_table graphicRef78919" href="/z/d/graphic/78919.html" rel="external">table 3</a>). (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biochemical findings</strong> –<strong> </strong>The initial laboratory evaluation includes measurement of glucose, insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea/meglitinide screening during an episode of hypoglycemia. In contrast to the biochemical findings in individuals with hyperinsulinemic hypoglycemia, patients with IGF-induced hypoglycemia have low serum insulin, C-peptide, and beta-hydroxybutyrate concentrations during hypoglycemia  (<a class="graphic graphic_algorithm graphicRef141454" href="/z/d/graphic/141454.html" rel="external">algorithm 2</a> and <a class="graphic graphic_table graphicRef56314" href="/z/d/graphic/56314.html" rel="external">table 2</a>). (See <a class="local">'Biochemical findings'</a> above and  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Interpretation of supervised fast results'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional testing</strong> – Measurement of IGF-1, IGF-2, and pro-IGF-2 may provide additional supportive data but is not always essential in patients with known malignancy and large tumor burden. (See <a class="local">'Additional testing to confirm the diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology", section on 'Interpretation of supervised fast results'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment</strong> – The treatment involves immediate correction of hypoglycemia, treatment directed at the underlying malignancy (typically surgery), and prevention of recurrent hypoglycemia if the tumor cannot be controlled. For medical therapy if the underlying malignancy cannot be treated, we suggest glucocorticoids as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A typical regimen is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 30 to 60 mg (or equivalent) daily. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus", section on 'Reversing hypoglycemia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Persistent hypoglycemia</strong> – If hypoglycemia persists, patients with a glycemic response to <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a> (eg, NICTH due to pro-IGF-2) can be treated with a long-term intravenous glucagon infusion (0.06 to 0.30 mg/hour). We prefer not to use growth hormone therapy, unless for palliation in end-stage cancer patients with NICTH. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H960614749"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges F John Service, MD, PhD, now deceased, who contributed to an earlier version of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Scott K. Non-islet cell tumor hypoglycemia. J Pain Symptom Manage 2009; 37:e1.</a></li><li><a class="nounderline abstract_t">Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab 2014; 99:713.</a></li><li><a class="nounderline abstract_t">Marks V, Teale JD. Tumours producing hypoglycaemia. Endocr Relat Cancer 1998; 5:111.</a></li><li><a class="nounderline abstract_t">Ma RC, Tong PC, Chan JC, et al. A 67-year-old woman with recurrent hypoglycemia: non-islet cell tumour hypoglycemia. CMAJ 2005; 173:359.</a></li><li><a class="nounderline abstract_t">Pink D, Schoeler D, Lindner T, et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. J Clin Oncol 2005; 23:6809.</a></li><li><a class="nounderline abstract_t">Dynkevich Y, Rother KI, Whitford I, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev 2013; 34:798.</a></li><li><a class="nounderline abstract_t">Eastman RC, Carson RE, Orloff DG, et al. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest 1992; 89:1958.</a></li><li><a class="nounderline abstract_t">Gorden P, Hendricks CM, Kahn CR, et al. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. N Engl J Med 1981; 305:1452.</a></li><li><a class="nounderline abstract_t">Shapiro ET, Bell GI, Polonsky KS, et al. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. J Clin Invest 1990; 85:1672.</a></li><li><a class="nounderline abstract_t">Zapf J, Futo E, Peter M, Froesch ER. Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J Clin Invest 1992; 90:2574.</a></li><li><a class="nounderline abstract_t">Phillips LS, Robertson DG. Insulin-like growth factors and non-islet cell tumor hypoglycemia. Metabolism 1993; 42:1093.</a></li><li><a class="nounderline abstract_t">Nauck MA, Reinecke M, Perren A, et al. Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab 2007; 92:1600.</a></li><li><a class="nounderline abstract_t">Shetty MR, Boghossian HM, Duffell D, et al. Tumor-induced hypoglycemia: a result of ectopic insulin production. Cancer 1982; 49:1920.</a></li><li><a class="nounderline abstract_t">Shames JM, Dhurandhar NR, Blackard WG. Insulin-secreting bronchial carcinoid tumor with widespread metastases. Am J Med 1968; 44:632.</a></li><li><a class="nounderline abstract_t">Kiang DT, Bauer GE, Kennedy BJ. Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia. Cancer 1973; 31:801.</a></li><li><a class="nounderline abstract_t">Seckl MJ, Mulholland PJ, Bishop AE, et al. Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 1999; 341:733.</a></li><li><a class="nounderline abstract_t">Frankton S, Baithun S, Husain E, et al. Phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension. Hormones (Athens) 2009; 8:65.</a></li><li><a class="nounderline abstract_t">Nadler WH, Wolfer JA. Hepatogenic hypoglycemic associated with primary liver cell carcinoma. Arch Intern Med 1929; 44:701.</a></li><li><a class="nounderline abstract_t">Fukuda I, Hizuka N, Ishikawa Y, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 2006; 16:211.</a></li><li><a class="nounderline abstract_t">Soares-Welch CV, Zeldenrust SR, Conover CA, et al. Hodgkin's lymphoma manifesting with hypoglycemia. Endocr Pract 2003; 9:96.</a></li><li><a class="nounderline abstract_t">Dyer PH, Chowdhury TA, Milles J. Recurrent hypoglycaemia. Postgrad Med J 1998; 74:279.</a></li><li><a class="nounderline abstract_t">Pun KK, Young RT, Wang C, et al. The use of glucagon challenge tests in the diagnostic evaluation of hypoglycemia due to hepatoma and insulinoma. J Clin Endocrinol Metab 1988; 67:546.</a></li><li><a class="nounderline abstract_t">Hoff AO, Vassilopoulou-Sellin R. The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia. Cancer 1998; 82:1585.</a></li><li><a class="nounderline abstract_t">Redmon B, Pyzdrowski KL, Elson MK, et al. Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myeloma. N Engl J Med 1992; 326:994.</a></li><li><a class="nounderline abstract_t">Walters EG, Tavaré JM, Denton RM, Walters G. Hypoglycaemia due to an insulin-receptor antibody in Hodgkin's disease. Lancet 1987; 1:241.</a></li><li><a class="nounderline abstract_t">de Boer J, Jager PL, Wiggers T, et al. The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. Int J Clin Oncol 2006; 11:478.</a></li><li><a class="nounderline abstract_t">Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf) 1998; 49:491.</a></li><li><a class="nounderline abstract_t">Perros P, Simpson J, Innes JA, et al. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clin Endocrinol (Oxf) 1996; 44:727.</a></li><li><a class="nounderline abstract_t">Morbois-Trabut L, Maillot F, De Widerspach-Thor A, et al. "Big IGF-II"-induced hypoglycemia secondary to gastric adenocarcinoma. Diabetes Metab 2004; 30:276.</a></li><li><a class="nounderline abstract_t">Bourcigaux N, Arnault-Ouary G, Christol R, et al. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther 2005; 27:246.</a></li><li><a class="nounderline abstract_t">Powter L, Phillips S, Husbands E. A case report of non-islet cell tumour hypoglycaemia associated with ovarian germ-cell tumour. Palliat Med 2013; 27:281.</a></li><li><a class="nounderline abstract_t">Mukherjee S, Diver M, Weston PJ. Non islet cell tumor hypoglycaemia in a metastatic Leydig cell tumor. Acta Oncol 2005; 44:761.</a></li><li><a class="nounderline abstract_t">Silveira LF, Bouloux PM, MacColl GS, et al. Growth hormone therapy for non-islet cell tumor hypoglycemia. Am J Med 2002; 113:255.</a></li><li><a class="nounderline abstract_t">Teale JD, Blum WF, Marks V. Alleviation of non-islet cell tumour hypoglycaemia by growth hormone therapy is associated with changes in IGF binding protein-3. Ann Clin Biochem 1992; 29 ( Pt 3):314.</a></li><li><a class="nounderline abstract_t">Drake WM, Miraki F, Siddiqi A, et al. Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia. Eur J Endocrinol 1998; 139:532.</a></li><li><a class="nounderline abstract_t">Agus MS, Katz LE, Satin-Smith M, et al. Non-islet-cell tumor associated with hypoglycemia in a child: successful long-term therapy with growth hormone. J Pediatr 1995; 127:403.</a></li></ol></div><div id="topicVersionRevision">Topic 1780 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345293" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Non-islet cell tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423303" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of non-islet-cell tumor hypoglycemia: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tumours producing hypoglycaemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103505" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A 67-year-old woman with recurrent hypoglycemia: non-islet cell tumour hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23671155" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1318326" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272111" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2159026" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1281841" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412760" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Insulin-like growth factors and non-islet cell tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17299065" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6280848" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tumor-induced hypoglycemia: a result of ectopic insulin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4296076" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Insulin-secreting bronchial carcinoid tumor with widespread metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4706048" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471459" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19269923" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Phaeochromocytoma crisis presenting with profound hypoglycaemia and subsequent hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatogenic hypoglycemic associated with primary liver cell carcinoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860583" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917097" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hodgkin's lymphoma manifesting with hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9713609" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrent hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2842361" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The use of glucagon challenge tests in the diagnostic evaluation of hypoglycemia due to hepatoma and insulinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9554538" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of glucagon administration in the diagnosis and treatment of patients with tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545852" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hypoglycemia due to a monoclonal insulin-binding antibody in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2880068" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hypoglycaemia due to an insulin-receptor antibody in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17180519" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876347" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759187" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223980" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : "Big IGF-II"-induced hypoglycemia secondary to gastric adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811488" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128903" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A case report of non-islet cell tumour hypoglycaemia associated with ovarian germ-cell tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227169" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Non islet cell tumor hypoglycaemia in a metastatic Leydig cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208393" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Growth hormone therapy for non-islet cell tumor hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376980" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Alleviation of non-islet cell tumour hypoglycaemia by growth hormone therapy is associated with changes in IGF binding protein-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849819" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658270" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Non-islet-cell tumor associated with hypoglycemia in a child: successful long-term therapy with growth hormone.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
